SlideShare a Scribd company logo
1 of 29
ECONOMIC EVALUATION
OF HEALTH INTERVENTIONS
Abdur Razzaque Sarker
MHE (Health Economics), MSS (Economics)
Health Economics and Financing Research, icddrb
and
PhD Fellow in Strathclyde University, UK
Email: razzaque.sarker@gmail.com
2
Topic
 Cost Analysis (Cont..)
 Cost Minimization Analysis
 Cost Effectiveness Analysis (CEA)
 Cost utility Analysis ( CUA)
 CEA/CUA Exercise
 Group Work
What is economic evaluation?
Economic evaluation is the comparative analysis of at
least two health care interventions or alternatives in
terms of both their costs and consequences.
3
 Cost‐Minimization Analysis
 Cost‐Effectiveness Analysis
 Cost‐Utility Analysis
 Cost‐Benefit Analysis
Types of Economic Evaluations
4
Cost‐Minimization Analysis
Compare the costs of two or more
interventions with identical outcome and
choose the least costly one.
5
Alternative A
Injury prevention by building a speed-breaker
Cost per injury prevented = 500 Taka
Number of injury prevented = 200
Alternative B
Injury prevention by building a foot over-bridge
Cost per injury prevented = 1200 Taka
Number of injury prevented = 200
The outcomes (number of injury prevented) are
identical for alternatives ‘A’ and ‘B’. Alternative ‘A’ has
lower cost of intervention. Using CMA, we can choose
alternative ‘A’, i.e. building a speed-breaker
Cost minimization analysis (CMA)
6
Cost-effectiveness analysis
(CEA)
Compare ‘cost per consequence’ of two or more
interventions, where the consequences are
measured by “natural” units (life years gained,
saved years of life)
7
Outcome
Years of life saved
Hospital days prevented
Number of case prevented
Reduction in cholesterol
Blood pressure reduction
8
Cost-effectiveness analysis (CEA)
 Cost-effectiveness ratio (CER)
 Incremental cost-effectiveness ratio (ICER)
9
If effectiveness of alternative ‘A’ is higher and its costs is lower than
those of alternative ‘B’.
Alternative ‘A’ is called dominant
Alternative ‘B’ is called dominated
Law of Dominance &
Law of Extended Dominance
Alternative Cost Saved years
of Life
'A' 2,000 600
'B' 3,000 500
Dominance
10
Extended dominance
If we compare the interventions based on ICERs, we choose that
programs which is ‘more effective, using law of extended dominance’.
One intervention (C) is said to be ‘extended dominant’ if its ICER is
lower than the previous intervention(B). And the rolled out
intervention is called ‘extended dominated’ (B).
Alternative Cost Effect C E C/E
‘No' 0 0 0 0 0
'A' 200 4 200 4 50
'B' 300 5 100 1 100
'C' 380 6 80 1 80
Alternative Cost Effect C E C/E
‘No' 0 0 0 0 0
'A' 200 4 200 4 50
'B' 300 5 100 1 100
'C' 380 6 80 1 80
Extendeddominated
Extendeddominant
11
12
Cost Utility Analysis ( CUA)
Cost-utility analysis
Compare ‘cost per consequence’ of
two or more interventions, where the
consequences are measured by
“utility” related to health (quality-
adjusted life years, disability adjusted
life years)
13
14
Cost-utility analysis
Unlike CEA, effects in CUA are measured in terms of
utility
- Quality-adjusted life years (QALYs)
- Disability-adjusted life years (DALYs)
15
Example
Program Cost per
patients (C)
life year
saved
Quality
increase
QALYs
gain (E)
No program 0 0 0 0
E (Pneumonia) 500 20 0.93 18.6
A (Polio) 100 10 0.92 9.2
D(Diphtheria) 400 19 0.88 16.72
C(Syphilis) 300 15 0.86 12.9
B (TB) 200 14 0.93 13.02
16
There are five different treatment (interventions) for producing
saved years of life (S YoL). Our aim is to choose those
interventions which survive the cost-effectiveness analysis and to
rank them from highest to lowest cost-effectiveness.
Cost per patients and S YoL are presented below. We assume
that each disease group has 200 patients to be treated.
Intervention Cost per
patients (C)
SYoL
(E)
No 0 0
E
(Pneumonia)
500 20
A (Polio) 100 10
D (Diphtheria ) 400 19
C (Syphilis) 300 15
B (TB) 200 14
Example of allocating resources using
cost-effectiveness and cost-utility analysis
17
Steps of choosing cost-effective interventions
1. Sort the interventions according to ‘cost per patient’ in
ascending order
2. Find dominated interventions
3. Keep the survived interventions using the same sorting
procedure as in step 1
4. Calculate ICER between interventions
5. Find the interventions which are ‘extended dominated’ and
roll them out
6. Keep the survived interventions
7. Calculate the ICER of the survived interventions and roll out
the ‘extended dominated interventions’ and continue this
process until all extended dominant interventions are rolled
out
8. Now you find the interventions which have survived the
cost-effectiveness analysis
18
Step 1: Sort in ascending order using cost of
treatment
Intervention Cost per patients (C) SYoL (E)
No 0 0
A (Polio) 100 10
B (TB) 200 14
C(syphilis) 300 15
D(Diptheria) 400 19
E (Pneumonia) 500 20
19
Intervention Cost per
patients (C)
SYoL
(E)
No 0 0
E (Pneumonia) 500 20
A (Polio) 100 10
D (Diphtheria ) 400 19
C (Syphilis) 300 15
B (TB) 200 14
Step 2: Find Dominated interventions
There is no dominated intervention
20
Intervention Cost per patients (C) SYoL (E)
No 0 0
A (Polio) 100 10
B (TB) 200 14
C(Syphilis) 300 15
D(Diptheria) 400 19
E (Pneumonia) 500 20
If effectiveness of alternative ‘A’ is higher and its costs is lower
than those of alternative ‘B’. Alternative ‘B’ is called dominated
21
Intervention Cost per patients (C) S YoL (E)
No 0 0
A (Polio) 100 10
B (TB) 200 14
C(syphilis) 300 15
D(Diptheria) 400 19
E (Pneumonia) 500 20
Step 3: Keep the survived interventions using step 1
All interventions are kept
Step 4: Calculate ICER between interventions
22
Intervention Cost per patients (C) SYoL (E) ∆C ∆E ∆C/∆E
No 0 0 0 0 0
A (Polio) 100 10 100 10 10
B (TB) 200 14 100 4 25
C(syphilis) 300 15 100 1 100
D(Diptheria) 400 19 100 4 25
E
(Pnumonia) 500 20 100 1 100
23
Step 5: Find ‘extended dominated’ interventions and roll
them out
Intervention Cost per
patients (C)
SYoL (E)
∆C ∆E ∆C/∆E
No 0 0 0 0 0
A (Polio) 100 10 100 10 10
B (TB) 200 14 100 4 25
C(syphilis) 300 15 100 1 100
D(Diphtheria) 400 19 100 4 25
E (Pneumonia) 500 20 100 1 100
One intervention (D) is said to be ‘extended dominant’ if its
ICER is lower than the previous intervention(C). Here,
alternative D is called the extended dominant alternative. And
the rolled out intervention is called ‘extended dominated’. Here ,
C is extended dominated by D.
Step 6: Keep the survived interventions
Intervention Cost per
patients (C)
S YoL (E)
No 0 0
A (Polio) 100 10
B (TB) 200 14
D(Diphtheria) 400 19
E (Pneumonia) 500 20
Step 7: Recalculate ICER of survived interventions and roll out
the ‘extended dominated interventions’
Intervention Cost per
patients (C)
S YoL (E)
∆C ∆E ∆C/∆E
No 0 0 0 0 0
A (Polio) 100 10 100 10 10
B (TB) 200 14 100 4 25
D(Diphtheria) 400 19 200 5 40
E (Pneumonia) 500 20 100 1 100
Observation: No ‘extended dominated intervention’ is found.
24
Step 8: Interventions which have survived the cost-effectiveness analysis
Intervention Cost per patients (C) S YoL (E)
No 0 0
A (Polio) 100 10
B (TB) 200 14
D(Diphtheria) 400 19
E (Pneumonia) 500 20
25
Here, A is most cost effective alternative.
Allocating budget among the
interventions
Conditions:
Total budget = US$ 80,000
Maximum 200 patients from each disease group can be treated
How to allocate?
We start allocating the budget in the most cost-effective
intervention (A) and gradually allocate in the next ones.
Alternative Cost per
patient
S YoL No of patients
treated
Total cost of
treatment
Budget
left
Total
S YoL
A 100 10 200 20,000 60,000 2,000
B 200 14 200 40,000 20,000 2,800
D 400 19 50 20,000 0 950
E 500 20
Total 450 80,000 5,750
Result:
Using the total budget (US$ 80,000 a sum of 450 patients can be treated w
Gives a total saved years of life (SYoL) of 5,750.
26
27
Any other combination gives maximum outcome
based on budget???
Alternative Cost per
patient
S YoL No of patients
treated
Total cost of
treatment
Budget
left
Total
SYol
B 200 14 200 40,000 40,000 2800
D 400 19 100 40,000 0 1900
A 100 10
E 500 20
Total 300 4700
Alternative Cost per patient S YoL No of patients
treated
Total cost of
treatment
Budget left Total SYol
D 400 19 200 80,000 0 3800
A 100 10
B 200 14
E 500 20
Total 200 3800
Exercise
28
THANKS
29
Email:
razzaque.sarker@gmail.com

More Related Content

What's hot

Economic Evaluation in Healthcare
Economic Evaluation in HealthcareEconomic Evaluation in Healthcare
Economic Evaluation in HealthcareDRRV
 
Cost effectiveness analysis in health care planning
Cost effectiveness analysis in health care planningCost effectiveness analysis in health care planning
Cost effectiveness analysis in health care planningNayyar Kazmi
 
Cost Effectiveness Analysis in Health economics
Cost Effectiveness Analysis in Health economicsCost Effectiveness Analysis in Health economics
Cost Effectiveness Analysis in Health economicsGerardo García
 
Economic evaluations health economics presentation
Economic evaluations   health economics presentationEconomic evaluations   health economics presentation
Economic evaluations health economics presentationAhmed Zaahir
 
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisPharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisMohammed Mohammed
 
Cost Utility Analysis
Cost Utility AnalysisCost Utility Analysis
Cost Utility AnalysisLanceCatedral
 
Cost Benefit Analysis in Health Care
Cost Benefit Analysis in Health CareCost Benefit Analysis in Health Care
Cost Benefit Analysis in Health CarePrabesh Ghimire
 
Cost minimisation analysis in health economics
Cost minimisation analysis in health economicsCost minimisation analysis in health economics
Cost minimisation analysis in health economicsa01071979
 
Concept of Economic Evaluation in Health Care
Concept of Economic Evaluation in Health CareConcept of Economic Evaluation in Health Care
Concept of Economic Evaluation in Health CarePrabesh Ghimire
 
Health economics
Health economicsHealth economics
Health economicsAmit Pagada
 
DALYs and QALYs by samrat gurung
DALYs and QALYs by samrat gurungDALYs and QALYs by samrat gurung
DALYs and QALYs by samrat gurungSamrat Gurung
 
Evaluation of health programs
Evaluation of health programsEvaluation of health programs
Evaluation of health programsnium
 
Concepts in health economics
Concepts in health economicsConcepts in health economics
Concepts in health economicsAparna Chaudhary
 
Cost benefit and cost effective analysis
Cost benefit and cost effective analysis Cost benefit and cost effective analysis
Cost benefit and cost effective analysis Mohamed Sheikh Omar
 

What's hot (20)

Economic Evaluation in Healthcare
Economic Evaluation in HealthcareEconomic Evaluation in Healthcare
Economic Evaluation in Healthcare
 
Cost effectiveness analysis in health care planning
Cost effectiveness analysis in health care planningCost effectiveness analysis in health care planning
Cost effectiveness analysis in health care planning
 
Cost Effectiveness Analysis in Health economics
Cost Effectiveness Analysis in Health economicsCost Effectiveness Analysis in Health economics
Cost Effectiveness Analysis in Health economics
 
Clinical pharmacy
Clinical pharmacyClinical pharmacy
Clinical pharmacy
 
Economic evaluations health economics presentation
Economic evaluations   health economics presentationEconomic evaluations   health economics presentation
Economic evaluations health economics presentation
 
Cost benifit analysis
Cost benifit analysisCost benifit analysis
Cost benifit analysis
 
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisPharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysis
 
Cost Utility Analysis
Cost Utility AnalysisCost Utility Analysis
Cost Utility Analysis
 
Cost Benefit Analysis in Health Care
Cost Benefit Analysis in Health CareCost Benefit Analysis in Health Care
Cost Benefit Analysis in Health Care
 
Cost minimisation analysis in health economics
Cost minimisation analysis in health economicsCost minimisation analysis in health economics
Cost minimisation analysis in health economics
 
Health economics
Health economicsHealth economics
Health economics
 
Concept of Economic Evaluation in Health Care
Concept of Economic Evaluation in Health CareConcept of Economic Evaluation in Health Care
Concept of Economic Evaluation in Health Care
 
Health economics
Health economicsHealth economics
Health economics
 
DALYs and QALYs by samrat gurung
DALYs and QALYs by samrat gurungDALYs and QALYs by samrat gurung
DALYs and QALYs by samrat gurung
 
Health economics
Health economicsHealth economics
Health economics
 
Evaluation of health programs
Evaluation of health programsEvaluation of health programs
Evaluation of health programs
 
HEALTH ECONOMICS
HEALTH ECONOMICSHEALTH ECONOMICS
HEALTH ECONOMICS
 
Health economics what is it
Health economics what is itHealth economics what is it
Health economics what is it
 
Concepts in health economics
Concepts in health economicsConcepts in health economics
Concepts in health economics
 
Cost benefit and cost effective analysis
Cost benefit and cost effective analysis Cost benefit and cost effective analysis
Cost benefit and cost effective analysis
 

Similar to Cost effectiveness analysis

Cost effective analysis in health care (Nursing) Naveen J H
Cost effective analysis in health care (Nursing) Naveen J HCost effective analysis in health care (Nursing) Naveen J H
Cost effective analysis in health care (Nursing) Naveen J HNaveen j h
 
Cost effective analysis in health care (Nursing) Naveen J H
Cost effective analysis in health care (Nursing) Naveen J HCost effective analysis in health care (Nursing) Naveen J H
Cost effective analysis in health care (Nursing) Naveen J HNaveen j h
 
I am thankful for her time and support, and for sharing her valuable insights...
I am thankful for her time and support, and for sharing her valuable insights...I am thankful for her time and support, and for sharing her valuable insights...
I am thankful for her time and support, and for sharing her valuable insights...ManikIslam9
 
Distinguishing Externalities and Internalization
Distinguishing Externalities and InternalizationDistinguishing Externalities and Internalization
Distinguishing Externalities and InternalizationSSA KPI
 
Maureen Cronin
Maureen CroninMaureen Cronin
Maureen CroninIMSTA
 
Hen 368 lecture 5 cost and benefit evaluation methods
Hen 368 lecture 5 cost and benefit evaluation methodsHen 368 lecture 5 cost and benefit evaluation methods
Hen 368 lecture 5 cost and benefit evaluation methodsGale Pooley
 
Pain Procedure Valuation as a Competitive Strategy
Pain Procedure Valuation as a Competitive StrategyPain Procedure Valuation as a Competitive Strategy
Pain Procedure Valuation as a Competitive StrategyJAMES B. MACON, M.D.
 
costeffectivenessanalysis-190329224533.pdf
costeffectivenessanalysis-190329224533.pdfcosteffectivenessanalysis-190329224533.pdf
costeffectivenessanalysis-190329224533.pdfzaki417475
 
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014GlobalResearchUCSF
 
Estimating cumulated absorbed doses and associated health risks due to occupa...
Estimating cumulated absorbed doses and associated health risks due to occupa...Estimating cumulated absorbed doses and associated health risks due to occupa...
Estimating cumulated absorbed doses and associated health risks due to occupa...David Moriña Soler
 
Financial model 300 bed teaching hospital (midwest) rev 0
Financial model 300 bed teaching hospital (midwest)  rev 0Financial model 300 bed teaching hospital (midwest)  rev 0
Financial model 300 bed teaching hospital (midwest) rev 0Lauraine Palm Singh,
 
Economic analysis on art task shifting ppp (for athens conference)
Economic analysis on art task shifting ppp (for athens conference)Economic analysis on art task shifting ppp (for athens conference)
Economic analysis on art task shifting ppp (for athens conference)Naod Mekonnen
 
Estimating cumulated doses and associated health risks due to occupational ex...
Estimating cumulated doses and associated health risks due to occupational ex...Estimating cumulated doses and associated health risks due to occupational ex...
Estimating cumulated doses and associated health risks due to occupational ex...David Moriña Soler
 
CHAPTER 4 Estimating CostsIntroduction to managerial account.docx
CHAPTER 4 Estimating CostsIntroduction to managerial account.docxCHAPTER 4 Estimating CostsIntroduction to managerial account.docx
CHAPTER 4 Estimating CostsIntroduction to managerial account.docxrobertad6
 

Similar to Cost effectiveness analysis (20)

Cost effective analysis in health care (Nursing) Naveen J H
Cost effective analysis in health care (Nursing) Naveen J HCost effective analysis in health care (Nursing) Naveen J H
Cost effective analysis in health care (Nursing) Naveen J H
 
Cost effective analysis in health care (Nursing) Naveen J H
Cost effective analysis in health care (Nursing) Naveen J HCost effective analysis in health care (Nursing) Naveen J H
Cost effective analysis in health care (Nursing) Naveen J H
 
I am thankful for her time and support, and for sharing her valuable insights...
I am thankful for her time and support, and for sharing her valuable insights...I am thankful for her time and support, and for sharing her valuable insights...
I am thankful for her time and support, and for sharing her valuable insights...
 
Cost analysis
Cost analysisCost analysis
Cost analysis
 
Distinguishing Externalities and Internalization
Distinguishing Externalities and InternalizationDistinguishing Externalities and Internalization
Distinguishing Externalities and Internalization
 
He
HeHe
He
 
Pharmaeconomic
Pharmaeconomic Pharmaeconomic
Pharmaeconomic
 
Maureen Cronin
Maureen CroninMaureen Cronin
Maureen Cronin
 
Hen 368 lecture 5 cost and benefit evaluation methods
Hen 368 lecture 5 cost and benefit evaluation methodsHen 368 lecture 5 cost and benefit evaluation methods
Hen 368 lecture 5 cost and benefit evaluation methods
 
Pain Procedure Valuation as a Competitive Strategy
Pain Procedure Valuation as a Competitive StrategyPain Procedure Valuation as a Competitive Strategy
Pain Procedure Valuation as a Competitive Strategy
 
costeffectivenessanalysis-190329224533.pdf
costeffectivenessanalysis-190329224533.pdfcosteffectivenessanalysis-190329224533.pdf
costeffectivenessanalysis-190329224533.pdf
 
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
 
Tomas Philipson
Tomas PhilipsonTomas Philipson
Tomas Philipson
 
Quality Lowers Cost: The Cost Effectiveness of a Multicenter Treatment Bundle...
Quality Lowers Cost: The Cost Effectiveness of a Multicenter Treatment Bundle...Quality Lowers Cost: The Cost Effectiveness of a Multicenter Treatment Bundle...
Quality Lowers Cost: The Cost Effectiveness of a Multicenter Treatment Bundle...
 
Estimating cumulated absorbed doses and associated health risks due to occupa...
Estimating cumulated absorbed doses and associated health risks due to occupa...Estimating cumulated absorbed doses and associated health risks due to occupa...
Estimating cumulated absorbed doses and associated health risks due to occupa...
 
Financial model 300 bed teaching hospital (midwest) rev 0
Financial model 300 bed teaching hospital (midwest)  rev 0Financial model 300 bed teaching hospital (midwest)  rev 0
Financial model 300 bed teaching hospital (midwest) rev 0
 
Economic analysis on art task shifting ppp (for athens conference)
Economic analysis on art task shifting ppp (for athens conference)Economic analysis on art task shifting ppp (for athens conference)
Economic analysis on art task shifting ppp (for athens conference)
 
Estimating cumulated doses and associated health risks due to occupational ex...
Estimating cumulated doses and associated health risks due to occupational ex...Estimating cumulated doses and associated health risks due to occupational ex...
Estimating cumulated doses and associated health risks due to occupational ex...
 
CHAPTER 4 Estimating CostsIntroduction to managerial account.docx
CHAPTER 4 Estimating CostsIntroduction to managerial account.docxCHAPTER 4 Estimating CostsIntroduction to managerial account.docx
CHAPTER 4 Estimating CostsIntroduction to managerial account.docx
 
Pharmaeconomic
Pharmaeconomic Pharmaeconomic
Pharmaeconomic
 

More from Abdur Razzaque Sarker, PhD (15)

Scientific Report Writing.pdf
Scientific Report Writing.pdfScientific Report Writing.pdf
Scientific Report Writing.pdf
 
Cost Analysis_ Case Study
Cost Analysis_ Case StudyCost Analysis_ Case Study
Cost Analysis_ Case Study
 
Disability Adjusted Life Years
Disability Adjusted Life YearsDisability Adjusted Life Years
Disability Adjusted Life Years
 
Tools for health economics
Tools for health economicsTools for health economics
Tools for health economics
 
Measuring health
Measuring healthMeasuring health
Measuring health
 
Universal health coverage
Universal health coverageUniversal health coverage
Universal health coverage
 
Resource allocation
Resource allocationResource allocation
Resource allocation
 
Health system
Health systemHealth system
Health system
 
Health insurence
Health insurenceHealth insurence
Health insurence
 
Equity in health system
Equity in health systemEquity in health system
Equity in health system
 
Basics health economics
Basics health economicsBasics health economics
Basics health economics
 
Micro economics tools for health economics
Micro economics tools for health economicsMicro economics tools for health economics
Micro economics tools for health economics
 
Health economics an overview
Health economics an overviewHealth economics an overview
Health economics an overview
 
Burden of Disease using DALYs
Burden of Disease using DALYsBurden of Disease using DALYs
Burden of Disease using DALYs
 
Disabilty Adjusted Life Years(DALYs)
Disabilty Adjusted Life Years(DALYs)Disabilty Adjusted Life Years(DALYs)
Disabilty Adjusted Life Years(DALYs)
 

Recently uploaded

MVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady PresentationMVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady PresentationMVP Health Care
 
EHR Market Growth is The Boom Over - Jasper Colin
EHR Market Growth is The Boom Over - Jasper ColinEHR Market Growth is The Boom Over - Jasper Colin
EHR Market Growth is The Boom Over - Jasper ColinJasper Colin
 
Single Assessment Framework - What We Know So Far
Single Assessment Framework - What We Know So FarSingle Assessment Framework - What We Know So Far
Single Assessment Framework - What We Know So FarCareLineLive
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Oleg Kshivets
 
unit-3 blood product B.Pharma 3rd year .pptx
unit-3 blood product B.Pharma 3rd year .pptxunit-3 blood product B.Pharma 3rd year .pptx
unit-3 blood product B.Pharma 3rd year .pptxBkGupta21
 
TEENAGE PREGNANCY PREVENTION AND AWARENESS
TEENAGE PREGNANCY PREVENTION AND AWARENESSTEENAGE PREGNANCY PREVENTION AND AWARENESS
TEENAGE PREGNANCY PREVENTION AND AWARENESSPeterJamesVitug
 
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfUnderstanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfSasikiranMarri
 
Lipid Profile test & Cardiac Markers for MBBS, Lab. Med. and Nursing.pptx
Lipid Profile test & Cardiac Markers for MBBS, Lab. Med. and Nursing.pptxLipid Profile test & Cardiac Markers for MBBS, Lab. Med. and Nursing.pptx
Lipid Profile test & Cardiac Markers for MBBS, Lab. Med. and Nursing.pptxRajendra Dev Bhatt
 
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdfPreventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdfAditiAlishetty
 
FAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptxFAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptxMumux Mirani
 
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdfeurohealthleaders
 
Mental Health for physiotherapy and other health students
Mental Health for physiotherapy and other health studentsMental Health for physiotherapy and other health students
Mental Health for physiotherapy and other health studentseyobkaseye
 
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...Dr. David Greene Arizona
 
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are HeardAdvance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are HeardVITASAuthor
 
Clinical Education Presentation at Accelacare
Clinical Education Presentation at AccelacareClinical Education Presentation at Accelacare
Clinical Education Presentation at Accelacarepablor40
 
What are weight loss medication services?
What are weight loss medication services?What are weight loss medication services?
What are weight loss medication services?Optimal Healing 4u
 
Professional Ear Wax Cleaning Services for Your Home
Professional Ear Wax Cleaning Services for Your HomeProfessional Ear Wax Cleaning Services for Your Home
Professional Ear Wax Cleaning Services for Your HomeEarwax Doctor
 
arpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationarpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationNursing education
 

Recently uploaded (20)

MVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady PresentationMVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady Presentation
 
EHR Market Growth is The Boom Over - Jasper Colin
EHR Market Growth is The Boom Over - Jasper ColinEHR Market Growth is The Boom Over - Jasper Colin
EHR Market Growth is The Boom Over - Jasper Colin
 
Single Assessment Framework - What We Know So Far
Single Assessment Framework - What We Know So FarSingle Assessment Framework - What We Know So Far
Single Assessment Framework - What We Know So Far
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
 
unit-3 blood product B.Pharma 3rd year .pptx
unit-3 blood product B.Pharma 3rd year .pptxunit-3 blood product B.Pharma 3rd year .pptx
unit-3 blood product B.Pharma 3rd year .pptx
 
TEENAGE PREGNANCY PREVENTION AND AWARENESS
TEENAGE PREGNANCY PREVENTION AND AWARENESSTEENAGE PREGNANCY PREVENTION AND AWARENESS
TEENAGE PREGNANCY PREVENTION AND AWARENESS
 
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfUnderstanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
 
Lipid Profile test & Cardiac Markers for MBBS, Lab. Med. and Nursing.pptx
Lipid Profile test & Cardiac Markers for MBBS, Lab. Med. and Nursing.pptxLipid Profile test & Cardiac Markers for MBBS, Lab. Med. and Nursing.pptx
Lipid Profile test & Cardiac Markers for MBBS, Lab. Med. and Nursing.pptx
 
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdfPreventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
 
FAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptxFAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptx
 
Coping with Childhood Cancer - How Does it Hurt Today
Coping with Childhood Cancer - How Does it Hurt TodayCoping with Childhood Cancer - How Does it Hurt Today
Coping with Childhood Cancer - How Does it Hurt Today
 
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
 
Mental Health for physiotherapy and other health students
Mental Health for physiotherapy and other health studentsMental Health for physiotherapy and other health students
Mental Health for physiotherapy and other health students
 
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
 
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are HeardAdvance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
 
Clinical Education Presentation at Accelacare
Clinical Education Presentation at AccelacareClinical Education Presentation at Accelacare
Clinical Education Presentation at Accelacare
 
DELIRIUM psychiatric delirium is a organic mental disorder
DELIRIUM  psychiatric  delirium is a organic mental disorderDELIRIUM  psychiatric  delirium is a organic mental disorder
DELIRIUM psychiatric delirium is a organic mental disorder
 
What are weight loss medication services?
What are weight loss medication services?What are weight loss medication services?
What are weight loss medication services?
 
Professional Ear Wax Cleaning Services for Your Home
Professional Ear Wax Cleaning Services for Your HomeProfessional Ear Wax Cleaning Services for Your Home
Professional Ear Wax Cleaning Services for Your Home
 
arpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationarpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and education
 

Cost effectiveness analysis

  • 1. ECONOMIC EVALUATION OF HEALTH INTERVENTIONS Abdur Razzaque Sarker MHE (Health Economics), MSS (Economics) Health Economics and Financing Research, icddrb and PhD Fellow in Strathclyde University, UK Email: razzaque.sarker@gmail.com
  • 2. 2 Topic  Cost Analysis (Cont..)  Cost Minimization Analysis  Cost Effectiveness Analysis (CEA)  Cost utility Analysis ( CUA)  CEA/CUA Exercise  Group Work
  • 3. What is economic evaluation? Economic evaluation is the comparative analysis of at least two health care interventions or alternatives in terms of both their costs and consequences. 3
  • 4.  Cost‐Minimization Analysis  Cost‐Effectiveness Analysis  Cost‐Utility Analysis  Cost‐Benefit Analysis Types of Economic Evaluations 4
  • 5. Cost‐Minimization Analysis Compare the costs of two or more interventions with identical outcome and choose the least costly one. 5
  • 6. Alternative A Injury prevention by building a speed-breaker Cost per injury prevented = 500 Taka Number of injury prevented = 200 Alternative B Injury prevention by building a foot over-bridge Cost per injury prevented = 1200 Taka Number of injury prevented = 200 The outcomes (number of injury prevented) are identical for alternatives ‘A’ and ‘B’. Alternative ‘A’ has lower cost of intervention. Using CMA, we can choose alternative ‘A’, i.e. building a speed-breaker Cost minimization analysis (CMA) 6
  • 7. Cost-effectiveness analysis (CEA) Compare ‘cost per consequence’ of two or more interventions, where the consequences are measured by “natural” units (life years gained, saved years of life) 7
  • 8. Outcome Years of life saved Hospital days prevented Number of case prevented Reduction in cholesterol Blood pressure reduction 8
  • 9. Cost-effectiveness analysis (CEA)  Cost-effectiveness ratio (CER)  Incremental cost-effectiveness ratio (ICER) 9
  • 10. If effectiveness of alternative ‘A’ is higher and its costs is lower than those of alternative ‘B’. Alternative ‘A’ is called dominant Alternative ‘B’ is called dominated Law of Dominance & Law of Extended Dominance Alternative Cost Saved years of Life 'A' 2,000 600 'B' 3,000 500 Dominance 10
  • 11. Extended dominance If we compare the interventions based on ICERs, we choose that programs which is ‘more effective, using law of extended dominance’. One intervention (C) is said to be ‘extended dominant’ if its ICER is lower than the previous intervention(B). And the rolled out intervention is called ‘extended dominated’ (B). Alternative Cost Effect C E C/E ‘No' 0 0 0 0 0 'A' 200 4 200 4 50 'B' 300 5 100 1 100 'C' 380 6 80 1 80 Alternative Cost Effect C E C/E ‘No' 0 0 0 0 0 'A' 200 4 200 4 50 'B' 300 5 100 1 100 'C' 380 6 80 1 80 Extendeddominated Extendeddominant 11
  • 13. Cost-utility analysis Compare ‘cost per consequence’ of two or more interventions, where the consequences are measured by “utility” related to health (quality- adjusted life years, disability adjusted life years) 13
  • 14. 14
  • 15. Cost-utility analysis Unlike CEA, effects in CUA are measured in terms of utility - Quality-adjusted life years (QALYs) - Disability-adjusted life years (DALYs) 15
  • 16. Example Program Cost per patients (C) life year saved Quality increase QALYs gain (E) No program 0 0 0 0 E (Pneumonia) 500 20 0.93 18.6 A (Polio) 100 10 0.92 9.2 D(Diphtheria) 400 19 0.88 16.72 C(Syphilis) 300 15 0.86 12.9 B (TB) 200 14 0.93 13.02 16
  • 17. There are five different treatment (interventions) for producing saved years of life (S YoL). Our aim is to choose those interventions which survive the cost-effectiveness analysis and to rank them from highest to lowest cost-effectiveness. Cost per patients and S YoL are presented below. We assume that each disease group has 200 patients to be treated. Intervention Cost per patients (C) SYoL (E) No 0 0 E (Pneumonia) 500 20 A (Polio) 100 10 D (Diphtheria ) 400 19 C (Syphilis) 300 15 B (TB) 200 14 Example of allocating resources using cost-effectiveness and cost-utility analysis 17
  • 18. Steps of choosing cost-effective interventions 1. Sort the interventions according to ‘cost per patient’ in ascending order 2. Find dominated interventions 3. Keep the survived interventions using the same sorting procedure as in step 1 4. Calculate ICER between interventions 5. Find the interventions which are ‘extended dominated’ and roll them out 6. Keep the survived interventions 7. Calculate the ICER of the survived interventions and roll out the ‘extended dominated interventions’ and continue this process until all extended dominant interventions are rolled out 8. Now you find the interventions which have survived the cost-effectiveness analysis 18
  • 19. Step 1: Sort in ascending order using cost of treatment Intervention Cost per patients (C) SYoL (E) No 0 0 A (Polio) 100 10 B (TB) 200 14 C(syphilis) 300 15 D(Diptheria) 400 19 E (Pneumonia) 500 20 19 Intervention Cost per patients (C) SYoL (E) No 0 0 E (Pneumonia) 500 20 A (Polio) 100 10 D (Diphtheria ) 400 19 C (Syphilis) 300 15 B (TB) 200 14
  • 20. Step 2: Find Dominated interventions There is no dominated intervention 20 Intervention Cost per patients (C) SYoL (E) No 0 0 A (Polio) 100 10 B (TB) 200 14 C(Syphilis) 300 15 D(Diptheria) 400 19 E (Pneumonia) 500 20 If effectiveness of alternative ‘A’ is higher and its costs is lower than those of alternative ‘B’. Alternative ‘B’ is called dominated
  • 21. 21 Intervention Cost per patients (C) S YoL (E) No 0 0 A (Polio) 100 10 B (TB) 200 14 C(syphilis) 300 15 D(Diptheria) 400 19 E (Pneumonia) 500 20 Step 3: Keep the survived interventions using step 1 All interventions are kept
  • 22. Step 4: Calculate ICER between interventions 22 Intervention Cost per patients (C) SYoL (E) ∆C ∆E ∆C/∆E No 0 0 0 0 0 A (Polio) 100 10 100 10 10 B (TB) 200 14 100 4 25 C(syphilis) 300 15 100 1 100 D(Diptheria) 400 19 100 4 25 E (Pnumonia) 500 20 100 1 100
  • 23. 23 Step 5: Find ‘extended dominated’ interventions and roll them out Intervention Cost per patients (C) SYoL (E) ∆C ∆E ∆C/∆E No 0 0 0 0 0 A (Polio) 100 10 100 10 10 B (TB) 200 14 100 4 25 C(syphilis) 300 15 100 1 100 D(Diphtheria) 400 19 100 4 25 E (Pneumonia) 500 20 100 1 100 One intervention (D) is said to be ‘extended dominant’ if its ICER is lower than the previous intervention(C). Here, alternative D is called the extended dominant alternative. And the rolled out intervention is called ‘extended dominated’. Here , C is extended dominated by D.
  • 24. Step 6: Keep the survived interventions Intervention Cost per patients (C) S YoL (E) No 0 0 A (Polio) 100 10 B (TB) 200 14 D(Diphtheria) 400 19 E (Pneumonia) 500 20 Step 7: Recalculate ICER of survived interventions and roll out the ‘extended dominated interventions’ Intervention Cost per patients (C) S YoL (E) ∆C ∆E ∆C/∆E No 0 0 0 0 0 A (Polio) 100 10 100 10 10 B (TB) 200 14 100 4 25 D(Diphtheria) 400 19 200 5 40 E (Pneumonia) 500 20 100 1 100 Observation: No ‘extended dominated intervention’ is found. 24
  • 25. Step 8: Interventions which have survived the cost-effectiveness analysis Intervention Cost per patients (C) S YoL (E) No 0 0 A (Polio) 100 10 B (TB) 200 14 D(Diphtheria) 400 19 E (Pneumonia) 500 20 25 Here, A is most cost effective alternative.
  • 26. Allocating budget among the interventions Conditions: Total budget = US$ 80,000 Maximum 200 patients from each disease group can be treated How to allocate? We start allocating the budget in the most cost-effective intervention (A) and gradually allocate in the next ones. Alternative Cost per patient S YoL No of patients treated Total cost of treatment Budget left Total S YoL A 100 10 200 20,000 60,000 2,000 B 200 14 200 40,000 20,000 2,800 D 400 19 50 20,000 0 950 E 500 20 Total 450 80,000 5,750 Result: Using the total budget (US$ 80,000 a sum of 450 patients can be treated w Gives a total saved years of life (SYoL) of 5,750. 26
  • 27. 27 Any other combination gives maximum outcome based on budget??? Alternative Cost per patient S YoL No of patients treated Total cost of treatment Budget left Total SYol B 200 14 200 40,000 40,000 2800 D 400 19 100 40,000 0 1900 A 100 10 E 500 20 Total 300 4700 Alternative Cost per patient S YoL No of patients treated Total cost of treatment Budget left Total SYol D 400 19 200 80,000 0 3800 A 100 10 B 200 14 E 500 20 Total 200 3800